Iovance BiotherapeuticsIOVA -0.94%44 Gross Margin % is 40.50% as of Mar. 2026, which is 18% above its 10-year median of 34.28. GuruFocus rates IOVA with a GF Score™ of 44/100 and a GF Value™ of $18.83 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 738 Biotechnology companies, Iovance Biotherapeutics ranks worse than 71.68% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Iovance Biotherapeutics had a gross margin of 40.50% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Iovance Biotherapeutics Gross Margin % Related Terms
Iovance Biotherapeutics Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IOVA vs HRMY, NRIX, ZYME: Gross Margin % Comparison
For the Biotechnology subindustry, Iovance Biotherapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iovance Biotherapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Iovance Biotherapeutics (IOVA) has a Gross Margin % of 40.50% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Iovance Biotherapeutics and its competitors. This is 18% above median its historical median of 34.28. Over the past decade, Iovance Biotherapeutics' Gross Margin % has ranged from 13.12 to 43.17. According to the industry distribution chart, Iovance Biotherapeutics ranks #529 out of 738 companies in the Biotechnology industry, placing it in the top 71.7%.
Is Iovance Biotherapeutics' Gross Margin % too high?
Iovance Biotherapeutics' current Gross Margin % of 40.50% is 18% above median its 10-year median of 34.28. Over the past 10 years, this metric has ranged from a low of 13.12 to a high of 43.17. The Biotechnology industry median Gross Margin % is 60.94. Iovance Biotherapeutics' value of 40.50% is 33.5% below this industry median. Based on the distribution chart, Iovance Biotherapeutics ranks #529 out of 738 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' Gross Margin % compare to HRMY and NRIX?
According to the Biotechnology industry distribution chart, Iovance Biotherapeutics ranks #529 out of 738 companies for Gross Margin %. This places Iovance Biotherapeutics in the lower half of its industry. The industry median Gross Margin % is 60.94. Iovance Biotherapeutics' value of 40.50% is 33.5% below this benchmark. Historically, Iovance Biotherapeutics' own Gross Margin % has ranged from 13.12 to 43.17 over the past decade. While the company's 10-year median is 34.28 vs. the industry median of 60.94, Iovance Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Iovance Biotherapeutics's current Gross Margin % of 40.50% is 33.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Iovance Biotherapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iovance Biotherapeutics's current Gross Margin % is 40.50%, which is 18% above median its own 10-year median of 34.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (IOVA) is currently considered Possible Value Trap. The stock's GF Value™ is $18.83, compared to a current price of $4.21 — trading 77.6% below its estimated fair value. The current Gross Margin % is 40.50%, which is 18% above median its 10-year median of 34.28 and 33.5% below the Biotechnology industry median of 60.94. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Iovance Biotherapeutics (IOVA), the current Gross Margin % is 40.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iovance Biotherapeutics (IOVA) Overvalued in 2026?
Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued.
The current stock price of $4.21 is trading 77.6% below its estimated GF Value™ of $18.83.
GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.
Key valuation signals for IOVA:
Gross Margin %: 40.50% (18% above median its 10-year median of 34.28)
GF Value™: $18.83 vs. price of $4.21 (77.6% below fair value)
Industry Position: 33.5% below the Biotechnology median (#529 of 738)
No single metric tells the full story. See the IOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score
Get the complete analysis for IOVA
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IOVA has been successfully added to your 
